Note on the use of browser cookies

Cookies are important to the proper functioning of a site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality, and deliver content tailored to your interests.
Click "Agree and Proceed" to accept our cookies policy and go directly to the site or click on "Privacy Policy" to see detailed informations about the data protection of this website.

Head Navigation (EN)

MODAG - Neuroscience Solutions

Press releases

 

MODAG Launches Out of Stealth Mode with Series A Financing of EUR 12 Million to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy (MODAG GmbH)
-- Dr. Torsten Matthias appointed CEO, scientific founder Prof. Dr. Armin Giese joins as CSO --
-- SERY technology in-licensed from Max-Planck Innovation GmbH to design next-generation candidate portfolio --

MODAG announced today the completion of a EUR 12 million Series A financing round, launching out of stealth mode to advance lead candidate anle138b into clinical development in Multiple System Atrophy (MSA).

Read more... 

 

New mouse model highlights promising potential drug for slowing Parkinson’s (Parkinson´s UK)
The results indicate that, when given early, the molecule Anle138b may restore dopamine levels and help slow or stop Parkinson’s in its tracks.
Researchers at the University of Cambridge, funded by Parkinson's UK, have developed a new animal model and shown that anle138b may slow down the progression of Parkinson's by targeting toxic alpha synuclein-clumps.

Read more... 

 

Putting the brakes on Parkinson’s

Experimental drug ameliorates symptoms of neurodegenerative brain disease in mice - Test substance slows down disease progression

Experimental drug interferes with different mechanisms associated to Alzheimer’s disease

New drug against Alzheimer's and Parkinson's on the way (Max-Planck-Gesellschaft)

Hope for the future (MODAG GmbH)